Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

191.16 -2.65 (-1.37%)
Streaming Delayed Price Updated: 2:40 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
57 58 Next >
News headline image
Eli Lilly's Alzheimer's Drug Faces UK Agency Block After Biogen's Medicine Rejection Over Cost, Safety ↗
The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent rejection of Biogen's lecanemab, leaving campaigners and experts disappointed. 
Via Benzinga
News headline image
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement ↗
The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated... 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For Biogen ↗
 
Via Benzinga
News headline image
New Study Reveals How Classical Music Could Revolutionize Depression Care
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... 
Via PressReach
News headline image
How Is The Market Feeling About Biogen? ↗
 
Via Benzinga
News headline image
Biogen Earnings Flat; Biotech Giant Raises Guidance ↗
Sales slightly topped. Shares edged higher early Thursday. 
Via Investor's Business Daily
News headline image
The Analyst Verdict: Biogen In The Eyes Of 12 Experts ↗
 
Via Benzinga
News headline image
A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys. ↗
These companies have approved Alzheimer's treatments that could generate billions in revenue for their respective businesses. 
Via The Motley Fool
News headline image
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review ↗
Apple and Meta had strong results, while AI spending remains robust. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings ↗
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. 
Via Benzinga
Topics Economy
News headline image
Biogen (BIIB) Q2 2024 Earnings Call Transcript ↗
BIIB earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday? ↗
Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market... 
Via Benzinga
News headline image
Biogen Q2 Earnings: Beats Consensus, Lifts 2024 Profit Forecast As New Drug Launches Expected To Offset Decline In Multiple Sclerosis Med Sales ↗
Biogen reported Q2 adjusted EPS of $5.28, surpassing the $4.03 consensus. Sales were $2.47 billion, narrowly beating the $2.38 billion consensus. Notable changes include a 5% drop in multiple sclerosis... 
Via Benzinga
News headline image
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November ↗
After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a... 
Via Benzinga
News headline image
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC)
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
News headline image
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy? ↗
Biogen stock has slipped 18% so far this year. 
Via The Motley Fool
News headline image
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events ↗
The European Medicines Agency's CHMP has rejected the approval of Eisai and Biogen's Alzheimer's treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards... 
Via Benzinga
News headline image
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug ↗
Biogen partner Eisai is planning to ask European regulators to re-examine their decision. 
Via Investor's Business Daily
News headline image
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
From Biogen Inc.
Via GlobeNewswire
News headline image
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints ↗
Sage Therapeutics and Biogen will end further development of SAGE-324 in ET, focusing instead on evaluating future steps. 
Via Benzinga
News headline image
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails ↗
The companies are no longer developing their drug for essential tremor treatment. 
Via Investor's Business Daily
News headline image
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst ↗
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
Via Benzinga
News headline image
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong ↗
Biogen previously decided against opting into Ionis' Angelman program. 
Via Investor's Business Daily
News headline image
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
From The Law Offices of Frank R. Cruz
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.